Results 121 to 130 of about 6,425 (142)

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis. [PDF]

PLoS One, 2020
Liu N, Hang T, Gao X, Yang W, Kong W, Lou Q, Yang J.   +6 more
europepmc   +1 more source

Assessing the Role of Soluble Suppression of Tumorigenicity-2 (sST2) in Patients With Pulmonary Embolism

International Journal of Clinical Practice
Ahmet Seyfeddin Gurbuz, Ahmet Taha Sahin, Serhat Kesriklioglu   +2 more
doaj   +1 more source

Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis. [PDF]

Clin Exp Nephrol
Bellos I, Marinaki S, Lagiou P, Benetou V.   +3 more
europepmc   +1 more source

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. [PDF]

Cardiovasc Diabetol, 2020
Demyanets S, Kaun C, Kaider A, Speidl W, Prager M, Oravec S, Hohensinner P, Wojta J, Rega-Kaun G.   +8 more
europepmc   +1 more source

Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure. [PDF]

Anatol J Cardiol, 2018
Öncel CR.
europepmc   +1 more source

Soluble Suppression of Tumorigenicity 2 and Echocardiography in Sepsis. [PDF]

Ann Lab Med, 2016
Yang HS, Hur M, Kim H, Magrini L, Marino R, Di Somma S, GREAT Network.   +6 more
europepmc   +1 more source

A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. [PDF]

J Geriatr Cardiol, 2017
Luk KS, Ip C, Gong MQ, Wong SH, Wu WK, Dong M, Li GP, Chan KP, Du YM, Liu T, Wong MC, Hui DSC, Tse G, International Health Informatics Study (IHIS) Network.   +13 more
europepmc   +1 more source

Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis. [PDF]

Biosci Rep, 2019
Gu L, Li J.
europepmc   +1 more source

Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients. [PDF]

Int J Med Sci, 2018
Seo SM, Kim SH, Kim Y, Yoon HE, Shin SJ.
europepmc   +1 more source

Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction. [PDF]

Med Sci Monit, 2018
Cui Y, Qi X, Huang A, Li J, Hou W, Liu K.   +5 more
europepmc   +1 more source